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Case Report
Introduction
Acute pancreatitis is defined as inflammation of the pancreas 
and is one of the common reasons for hospital admissions in 
the United States.1 It has multiple causes, with alcohol and 
gall stone disease contributing to 80% to 90% of cases.2 
Other reported causes include drugs, common bile duct 
obstructions secondary to neoplasms and sphincter of Oddi 
dysfunction, and metabolic alterations such as hypercalce-
mia or hypertriglyceridemia. Hypercalcemia associated with 
primary hyperparathyroidism contributes to 3.6% cases of 
pancreatitis cases, while pancreatitis induced by excess con-
sumption of over-the-counter (OTC) calcium carbonate is 
rare and very seldom reported in the literature.3,4 In this arti-
cle, we present the case of a young male with pancreatitis 
secondary to OTC calcium carbonate medications.
Case Description
A 35-year-old male with no significant past medical history 
was admitted for epigastric pain with radiation to the back 
associated with nausea and vomiting. He complained of 
fatigue, poor appetite, and increased urination. He had a his-
tory of gastroesophageal reflux disease for which he was tak-
ing OTC medications. His vital signs were stable. On 
examination, he appeared slightly confused, with dry skin 
and generalized abdominal tenderness. Blood work: white 
blood cells 16 400/µL, sodium 139 mmol/L, blood urea nitro-
gen 23 mg/dL, creatinine 2.6 mg/dL, aspartate aminotrans-
ferase 34 U/L, alanine aminotransferase 26 U/L, bicarbonate 
34 mmol/L, alkaline phosphatase 114 U/L, calcium 15.1 mg/
dL, triglyceride level 79 mg/dL, low-density lipoprotein 110 
mg/dL, lipase 560 U/L, albumin 3.9 g/dL, and negative for 
ethanol. Computed tomography scan of abdomen/pelvis 
showed pancreatitis with a normal biliary tract. He was 
treated with pain medications and ringer lactate fluid.
Further investigation showed low parathyroid hormone 
(PTH) = 18 pg/mL, low vitamin D (25) = 17 ng/mL, along 
with normal PTH-related peptide, vitamin D (1,25), serum 
protein electrophoresis, urine protein electrophoresis, and 
free light chain. The patient admitted that he had been taking 
7 to 8 tablets of 600 mg calcium carbonate per day over the 
past 3 weeks for acid reflux. His symptoms and calcium level 
gradually improved with ringer lactate, and he was dis-
charged after 6 days. He was educated on the side effects of 
excessive OTC drug use.
Discussion
Milk-alkali syndrome (MAS) is caused by increased con-
sumption of calcium and alkali products. MAS is character-
ized by the triad of hypercalcemia, renal failure, and 
metabolic alkalosis. Increased use of OTC drugs in patients 
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Abstract
Acute pancreatitis is caused by alcohol, gall stone disease, drugs, trauma, infections, and metabolic causes such as hypercalcemia 
and hyperlipidemia. Hypercalcemia-induced acute pancreatitis has been well documented but only rarely occurs due to over-
the-counter calcium carbonate. In this article, we present a case of over-the-counter calcium carbonate–induced acute 
pancreatitis.
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with osteoporosis and kidney failure can lead to a life-threat-
ening illness. In the early days after its discovery, MAS was 
associated with an increased mortality rate of 4.4%.5 MAS 
was first described by Hardt and Rivers in 1923.6 They attrib-
uted this syndrome to the Sippy regimen, which was devel-
oped in 1915 for peptic ulcer disease. The Sippy regimen 
comprised the hourly consumption of milk, cream, and a 
mixture of alkaline powders. Prior to the discovery of H2 
blockers and proton pump inhibitors, the Sippy regimen was 
commonly used in peptic ulcer disease.7 In the 1970s and 
1980s, MAS contributed to less than 2% of hospitalized 
patients with hypercalcemia, but this incidence has increased 
to 12% in recent years.8 MAS is now considered to be the 
third most common cause of hypercalcemia, after hyperpara-
thyroidism and malignant neoplasms. Some authors have 
suggested that this increased incidence is due to increased 
use of OTC drugs.9
The pathophysiology of MAS is classified into 2 phases: 
a generation phase and a maintenance phase. Excess calcium 
consumption increases serum calcium levels; this results in 
volume depletion from diuresis and natriuresis by activation 
of the calcium sensing receptor (CaSR), which stimulates 
renal tubular absorption of bicarbonate and decreases glo-
merular filtration rate. This decreased glomerular filtration 
rate reduces filtration of calcium, while volume depletion 
and metabolic alkalosis lead to increased renal absorption of 
calcium in order to maintain calcium homeostasis. The 
pathophysiology of hypercalcemia-induced pancreatitis is 
unclear, but high calcium levels are thought to lead to intra-
cellular activation of proteases.10-13 In addition to OTC drugs 
as an inciting factor for MAS, other cyclic pathophysiologic 
pathways that promote alkalosis, hypercalcemia, and renal 
failure can mimic MAS. MAS has been reported with the 
consumption of more than 4 to 5 g of calcium carbonate per 
day.9 These cases present in 3 forms: acute, subacute (cope 
syndrome), and chronic (Burnett syndrome).14 In the acute 
phase, patients present with symptoms of toxemia, such as 
nausea, vomiting, anorexia, dizziness, vertigo, and confu-
sion; and in chronic phase, they present with muscle aches, 
polyuria, polydipsia, psychosis, tremor, pruritis, and abnor-
mal calcifications. Ocular calcification, renal calcinosis, and 
rarely breast calcifications have been reported.15 The diagno-
sis is clinical, and a detailed history along with a physical can 
aid the diagnosis of MAS. Treatment is mostly supportive, 
with hydration and removal of the underlying causative 
agent.
According to the evidence discussed above, we conclude 
that medications should be reconciled on every patient 
encounter, including OTC medications, and patients should 
be educated about the side effects of excessive use. Daily 
elemental calcium intake should not exceed 2 g per day. 
However, MAS has also been reported with a lower calcium 
intake in patients on thiazides and with preexisting renal fail-
ure, as in our patient. Therefore, it is very important that all 
patients should be educated on various drug interactions in 
addition to information about daily calcium intake.
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